RxDoctor Payments Data

Julie Barnes, NP

Family · Windsor, NYNPI 1558308627

Payments from drug & device makers

$825in general payments, 2019–2025

Across 42 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$245
  • Phathom Pharmaceuticals, Inc.$212
  • Pfizer$90
  • AstraZeneca$48
  • Lilly USA, LLC$48
  • GSK$44
  • plus $138 from 5 others

What the payments were for

  • Food & beverage$825100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$825 in reported general payments places this provider in the 65th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$21,169
Medicare patients
91
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$45,513
RybelsusSemaglutide19$33,560
EliquisApixaban20$32,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$27,456
JanuviaSitagliptin Phosphate13$21,540
ArexvyRsvpref3 Antigen/As01e/Pf66$20,723
ShingrixVaricella-Zoster Ge/As01b/Pf23$5,087
Atorvastatin Calcium262$2,670
Albuterol Sulfate HfaAlbuterol Sulfate62$2,390
Metoprolol Succinate88$1,919
Levothyroxine Sodium72$1,306
Omeprazole66$919
Simvastatin92$816
Lisinopril110$802
Losartan Potassium63$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$25$79,07455 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$44$53,266113 claims
PfizerEliquis$90$32,28120 claims
MerckJanuvia$41$21,54013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,883 family providers in New York.

Other family in Windsor

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →